Photo by Tyler Prahm on Unsplash
- Clorox (NYSE: CLX) trades at ~$105.88 — approximately 65% below its own historical average P/E ratio (the stock price divided by annual earnings), a historically rare valuation discount.
- The stock's 4.7% annual dividend yield surpasses the 10-year U.S. Treasury yield of ~4.4%, meaning investors collect more income holding CLX than government bonds while waiting for a business recovery.
- Clorox's January 22, 2026 acquisition of GOJO Industries (makers of Purell) for $2.25 billion adds 680+ global patents and ~20 million institutional dispensers, deepening its supply chain reach into healthcare and education markets.
- Near-term earnings pressure from a 2023 cyberattack recovery is expected to resolve by FY2027, when analysts forecast a ~5% revenue rebound — a potential catalyst investors are watching closely.
What Happened
If you follow dividend investing, Clorox (NYSE: CLX) has been quietly building a case for income-focused investors. As of March 23, 2026, the stock trades at approximately $105.88 with a market capitalization (the total market value of all outstanding shares) of $13.55 billion. That price reflects a company navigating a challenging stretch — but one with a durable foundation that long-term stock analysis consistently highlights as a strength worth examining.
The most significant recent development: on January 22, 2026, Clorox announced the $2.25 billion cash acquisition of GOJO Industries, the private company behind Purell hand sanitizer. GOJO brings more than a brand name — it holds 680+ global patents and has roughly 20 million dispensers installed in hospitals, schools, and commercial facilities worldwide. For a consumer staples company, adding a hygiene brand with deep institutional supply chain penetration is a strategically meaningful expansion.
Clorox is simultaneously managing a recovery from a 2023 cyberattack that disrupted its ERP (enterprise resource planning — internal software used to manage operations) and CRM (customer relationship management) systems. That transition continues to weigh on near-term earnings. Most recently, Q2 FY2026 results (for the quarter ended December 31, 2025) showed net sales down 1% to $1.67 billion, with diluted EPS (earnings per share) falling 16% to $1.29, compared to $1.54 in the same period a year earlier — a clear sign the transitional period is still active before a projected FY2027 rebound.
Through all of this, Clorox has raised its dividend for 48 consecutive years — qualifying it as a formal Dividend Aristocrat, a designation reserved for S&P 500 companies with at least 25 straight years of increases. The annual dividend stands at $4.96 per share, yielding approximately 4.7% at current prices.
What the Data Tells Us
Building on those near-term pressures, the most important story in current investment research on Clorox is the valuation gap. The stock trades at a P/E ratio (the stock price divided by annual earnings per share — a standard measure of how expensive a stock is) of approximately 17.2 times. To put that in everyday terms: the market is currently pricing every dollar of Clorox's earnings at $17.20, compared to a historical average closer to $50. That's roughly 65% below its own long-run average, and 18% below the Consumer Defensive sector average of approximately 21 times. This kind of cross-company comparison is a standard part of sector analysis when evaluating relative value.
The income picture adds another layer of context. The Motley Fool framed it directly: "At 17 times earnings — historically cheap and 65% below its own average P/E — Clorox offers a 4.7% dividend yield that beats the 10-year Treasury yield of ~4.4%, essentially paying investors to wait for business recovery." When a consumer staples stock yields more than government bonds, it tends to attract attention in dividend-focused investment research circles.
On dividend sustainability, the FY2025 data is reassuring. Clorox generated $778 million in free cash flow (cash remaining after covering operations and capital expenses), comfortably covering its $602 million in dividend obligations — leaving $176 million as buffer. FY2025 adjusted EPS reached $7.72, up 25% year-over-year, demonstrating the underlying earnings power of the business when operating at full capacity.
The near-term picture is more nuanced. FY2026 EPS guidance stands at $5.95–$6.30, an 18–23% decline, with approximately $0.90 per share attributed to an inventory drawdown (a one-time accounting effect from the ERP transition). Current market trends point toward FY2027 as the recovery year, with analysts projecting ~5% revenue growth once the system overhaul fully resolves.
Analyst consensus places a price target of $121.08 on CLX (range: $94–$150), implying roughly 8% upside from current levels. Notably, no analysts currently hold an outright Buy rating — the breakdown is 0 Buy, 10 Hold, and 3 Sell. Bear-case analysts targeting $94 flag leverage risk: the GOJO deal ($2.25B) plus a P&G Glad venture buyout ($476M) total approximately $2.7 billion in obligations against just $227 million in cash on hand — a tension any honest stock analysis must acknowledge. Additionally, potential removal from the FTSE All-World Index could trigger automatic institutional selling, a near-term market trends risk that may create a lower entry point for patient investors.
Key Companies and Supply Chain
A complete sector analysis of Clorox requires understanding where it sits in the consumer staples supply chain — and which adjacent players are worth researching for comparison.
Clorox (NYSE: CLX) — The anchor of this analysis. Clorox's portfolio spans cleaning products (Clorox bleach, Pine-Sol), health and wellness (Burt's Bees), and home products (Glad bags, Kingsford charcoal). The GOJO deal extends its supply chain into professional hygiene and institutional B2B (business-to-business) markets, adding recurring dispenser-refill revenue from hospitals and schools. With a $13.55 billion market cap and 48 consecutive years of dividend growth, it remains one of the more recognizable income names in consumer staples.
GOJO Industries (Private — now a Clorox subsidiary) — Post-acquisition, GOJO contributes 680+ global patents, the Purell brand, and ~20 million installed dispensers in high-traffic institutional settings. The deal is projected to deliver $50 million or more in annual cost synergies, be EPS-neutral in year one, and become accretive (earnings-additive) in year two — adding an estimated 30–50 basis points (0.30–0.50%) to Clorox's long-term growth rate.
Procter & Gamble (NYSE: PG) — Clorox recently bought out P&G's stake in their Glad joint venture for $476 million. P&G remains a key benchmark in sector analysis of consumer staples — typically trading at a premium to Clorox — making Clorox's current 18% discount to the sector average more striking for investment research comparisons.
Reckitt Benckiser (LON: RKT) and SC Johnson (Private) — Direct competitors in household cleaning and hygiene supply chain segments; useful benchmarks for tracking pricing power and raw material cost trends across the sector.
What Should You Do? 3 Action Steps
The data shows Clorox trading at ~17.2x earnings — 65% below its historical average P/E and 18% below sector peers. Worth researching independently: whether the FY2026 earnings dip is truly temporary (as most analysts believe) or signals a more permanent shift. Review the FY2027 revenue recovery forecast alongside today's price to develop your own view on fair value before making any capital allocation decision.
Investment research on any income stock should include a debt coverage review. Clorox's $778 million FY2025 free cash flow comfortably covered its $602 million dividend — but the ~$2.7 billion in new obligations from GOJO and the Glad buyout substantially increases leverage. Worth tracking: the pace of debt reduction over the next four to six quarters and any signals of a slowdown in future dividend growth.
Two near-term events — the GOJO integration (targeting $50M+ in synergies, with EPS accretion expected in year two) and the potential FTSE All-World Index removal — could both influence the share price in the next 6–12 months. Investors are watching these as potential entry signals. Set a calendar reminder to review quarterly earnings calls for integration updates and any index rebalancing announcements.
Frequently Asked Questions
Is Clorox CLX a good dividend stock to buy with $5,000 in 2026?
Based on current data, Clorox presents a notable case for income-focused investment research. A $5,000 position at ~$105.88 would purchase approximately 47 shares, generating roughly $233 in annual dividend income at $4.96/share — a 4.7% yield that exceeds the current 10-year Treasury rate of ~4.4%. Whether that's appropriate depends on your personal risk tolerance and time horizon. The near-term EPS decline, $2.7 billion in new leverage, and potential index removal are real risks to weigh carefully. This analysis is educational only; consult a licensed financial advisor before investing.
How safe is Clorox's dividend after the $2.25 billion GOJO acquisition in 2026?
FY2025 data suggests the dividend is currently sustainable: $778 million in free cash flow covered $602 million in dividend obligations. However, the combined ~$2.7 billion in new debt from GOJO and the Glad venture buyout significantly increases leverage (the ratio of debt to earnings capacity). Bear-case analysts specifically target $94/share because of this risk. Investors are watching future free cash flow generation and the debt paydown timeline as the key variables determining whether the 48-year dividend growth streak can be maintained.
Why is Clorox stock trading 65% below its historical average P/E ratio right now?
The primary driver is earnings pressure from the 2023 cyberattack, which forced a costly overhaul of Clorox's ERP and CRM systems. That transition continues to suppress near-term earnings: FY2026 EPS guidance of $5.95–$6.30 is 18–23% below FY2025's $7.72. Current market trends suggest analysts expect earnings to normalize in FY2027, potentially closing the valuation gap. The current P/E of ~17.2x sits 18% below the Consumer Defensive sector average of ~21x — a discount on top of a discount that income-focused stock analysis flags as worth monitoring.
What happens to Clorox stock if it gets removed from the FTSE All-World Index in 2026?
Index removal typically triggers automatic selling by passively managed funds that track the index, creating near-term downward price pressure. Investors watching market trends often view these events as potential entry points rather than reasons to avoid a stock, since Clorox's underlying fundamentals — revenue, dividend policy, and free cash flow generation — are not directly affected by index inclusion status. The removal risk is worth including in any stock analysis as a near-term technical factor, not a signal of deteriorating business quality.
How does Clorox compare to other Dividend Aristocrat stocks for income investors in 2026?
Within a broader sector analysis of Dividend Aristocrats, Clorox stands out primarily for its valuation discount and above-Treasury yield. Most peers with cleaner near-term earnings trade at or above the Consumer Defensive sector average P/E of ~21x. Clorox's 17.2x represents a meaningful discount worth including in any investment research comparison. Peers like Procter & Gamble (NYSE: PG), Colgate-Palmolive (NYSE: CL), and Church & Dwight (NYSE: CHD) offer useful benchmarks — each with different leverage profiles, yield levels, and supply chain exposures that make direct comparison instructive for income investors building a diversified portfolio.
Explore Our Network
Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice, a recommendation, or an endorsement of any security. Always do your own research and consult a licensed financial advisor before making investment decisions.
No comments:
Post a Comment